289 results about "CD3 Antibody" patented technology

The invention relates to the technical field of biological medicines, and particularly discloses an anti-human CD3 rabbit recombinant monoclonal antibody as well as a preparation method and application thereof. The antibody obtains anti-CD3 immune response by immunizing a rabbit, is obtained by combining single B cell sorting, gene cloning and a mammalian cell expression system, and has high affinity and good specificity. The antibody can effectively recognize CD3 positive T cells in human peripheral blood and can be applied to the fields of flow cytometry, immunohistochemistry, T cell function research and the like. Experimental results show that the antibody has the advantages of high titer, strong fluorescence signal, low background and the like, and is superior to the traditional murine anti-CD3 antibody. Amino acid sequences of light chain and heavy chain variable regions of the antibody are further obtained, and controllability and repeatability of antibody expression are achieved. The antibody has important scientific research value and industrial application prospect, and is suitable for various scenes such as T cell marker detection, immune state evaluation, immunotherapy auxiliary research and the like.

A hydrogel particle, comprising a matrix comprising a polymerized monomer, said matrix comprising a plurality of micropores and a plurality of macropores, and one or more immunostimulatory biomolecules selected from the group consisting of an anti-CD3 antibody or antigen-binding fragment thereof, an anti-CD28 antibody or antigen-binding fragment thereof, and combinations thereof.

Provided are an anti-CD3 antibody or an antigen-binding fragment thereof, and a use thereof. The anti-CD3 antibody comprises: heavy chain variable region CDRs and light chain variable region CDRs, the heavy chain variable region CDRs having amino acid sequences as shown in any one of SEQ ID NOs: 1-3, 7-8 and 74-86 or a conservatively modified form thereof, and / or the light chain variable region CDRs having amino acid sequences as shown in any one of SEQ ID NOs: 4-6, 9 and 87-92 or a conservatively modified form thereof. The provided anti-CD3 antibody or antigen-binding fragment thereof can bind to human CD3 protein and reduce the production of pro-inflammatory cytokines, and a bispecific antibody constructed using same has high PBMC tumor-killing activity and weak promotion of the secretion of pro-inflammatory cytokines. A pharmaceutical composition prepared using the anti-CD3 antibody or the antigen-binding fragment thereof or a multi-specific antibody thereof has better safety, and has value for clinical applications and drug development.

The invention provides a bispecific antibody targeting CD3 and MICA and an application of the bispecific antibody. The present invention relates to a conjugate comprising: a first antigen binding region comprising an anti-CD3 antibody or an antigen binding fragment thereof; the present invention relates to an anti-CD3 antibody or an antigen-binding fragment thereof, comprising a first antigen-binding region having MICA binding activity, a second antigen-binding region having MICA binding activity, the anti-CD3 antibody or the antigen-binding fragment thereof comprising a first heavy chain variable region having a specific CDRs amino acid sequence and a first light chain variable region. The bispecific antibody disclosed by the invention can be combined with CD3 and MICA so as to promote T cell activation, secrete cell factors and effectively promote PBMC (peripheral blood mononuclear cells) to kill tumor cells, so that the bispecific antibody has good anti-cancer activity; moreover, the bispecific antibody has reduced proinflammatory cytokine secretion promotion performance and T cell activation promotion performance, is higher in safety, and has good clinical application value and drug development value.

The invention relates to the technical field of nano-drug presentation systems, in particular to a TCR (T cell receptor) nano-vesicle antibody with both T cell redirection and immunosuppression reversal as well as a preparation method and application of the TCR nano-vesicle antibody. The TCR nano-vesicle antibody comprises a vesicle formed by a liposome and a cell membrane; tCR protein, a PD-1 antibody and a CD3 antibody are loaded on the vesicles. The nano vesicle antibody has the functions of T cell redirection and immunosuppression reversion; the difficulty of low stability of the soluble TCR is overcome; the polypeptide can be rapidly enriched in tumor tissues through tumor specificity TCR, and CD8 + T cells infiltrated by tumors are directly activated through an anti-CD3 antibody; depletion of T cells can be reversed through the PD-1 antibody on the surface, and the effector function of tumor infiltration CD8 + T cells is improved. The technical scheme can solve the technical problems that the TCR stability is not ideal and the immunosuppression state of the tumor microenvironment is difficult to overcome, and has ideal application and popularization prospects.

The present invention provides an antibody composition for detecting multiple myeloma based on full-spectrum flow cytometry and its application, belonging to the technical field of multiple myeloma detection. The antibody composition includes CD3 antibody, CD20 antibody, HLA-DR antibody, CD8 antibody, CD11b antibody, CD10 antibody, CD71 antibody, CD28 antibody, CD14 antibody, CD13 antibody, Igκ antibody, CD15 antibody, Igλ antibody, CD117 antibody, CD56 antibody, CD45 antibody, CD19 antibody, CD34 antibody, CD138 antibody, CD4 antibody, CD38 antibody, CD22 antibody and CD27 antibody. The kit containing the antibody composition can be applied to a full-spectrum flow cytometer to accurately perform preliminary screening on patients with multiple myeloma.

The invention belongs to the technical field of biology, and discloses an anti-human AXL antibody, a gene and application of the anti-human AXL antibody, and amino acid sequences of a heavy chain variable region and a light chain variable region of the anti-human AXL antibody are respectively shown as SEQ ID NO: 23-34. The anti-human AXL antibodies in some examples have the binding capacity EC50 value smaller than 2 nM for AXL antigens and have no binding capacity for irrelevant antigens Her2 and BSA, and it is indicated that the screened targeted AXL antibodies have high specificity and high binding activity. Different AXL / CD3 bispecific antibodies prepared on the basis of the anti-human AXL antibody have relatively strong killing ability (IC50: 0.1-0.5 nM) on AXL positive MDA-MB-231 cells, and have very low killing ability on AXL negative SKBR3 cells, so that off-target toxicity of the different AXL / CD3 antibodies is avoided, and the application of the different AXL / CD3 bispecific antibodies is further widened.

The invention provides an anti-CD28 humanized single-domain antibody and a preparation method of the anti-CD28 humanized single-domain antibody. Specifically, the invention discloses a plurality of single-domain antibodies targeting CD28, humanized antibodies thereof, derived proteins, gene sequences for encoding the single-domain antibodies and the humanized antibodies, and expression vectors and expression systems for producing the single-domain antibodies and the humanized antibodies. The single-domain antibody provided by the invention is a CD28 non-agonistic antibody, can block the binding of CD28 and CD80, and can specifically bind to CD28 of human and monkeys. The single-domain antibody provided by the invention has high safety, and provides a research and development basis for development of antibody coupling drugs and multispecific antibody drugs. A bispecific antibody composed of the CD28 single-domain antibody and the targeting tumor antigen antibody can significantly enhance the activity of the CD3 bispecific antibody. The activity of a multi-specific antibody composed of the CD28 single-domain antibody, the targeting tumor antigen antibody and the CD3 antibody is significantly superior to that of the CD3 bispecific antibody.

The invention relates to the technical field of genetic engineering antibodies, in particular to a bispecific antibody combined with BCMA and CD3 as well as a preparation method and application of the bispecific antibody. The invention provides a bispecific antibody which can be combined with BCMA and CD3 at the same time, has a specific targeting effect and can efficiently excite oriented immune response. The bispecific antibody well retains the biological functions of an anti-CD3 antibody and an anti-BCMA antibody, realizes that one bispecific antibody molecule simultaneously has an excellent BCMA and CD3 targeted binding biological function, can build a bridge between tumor cells and immune effector cells, effectively activates the immune effector cells and oriented immune response, and has a good application prospect. The tumor cell killing effect of immune cells is remarkably enhanced, the target cell killing efficiency is high, the ADCC effect is reduced to the maximum degree, high safety is achieved, and good application prospects are achieved in tumor immunotherapy.

The invention relates to an antibody composition for detecting abnormal CTL (cytotoxic T lymphocyte) cells of hemophagocytic syndrome and application of the antibody composition, and the antibody composition comprises a CD2 antibody, a CD3 antibody, a CD4 antibody, a CD5 antibody, a CD7 antibody, a CD8 antibody, a CD56 antibody, a CD57 antibody, a Granzyme B antibody, a Perforin antibody, a TRBC1 antibody and a CD45 antibody. In the technical scheme provided by the invention, key phenotypic characteristics of CTL (Cytotoxic Lymphocyte) can be completely covered by various antibodies aiming at T cell and NK cell surface markers, T large granular lymphocyte markers, cytotoxic granular proteins, T cell receptor constant regions and leukocyte common antigens; wherein the clonality of the CTL cells is judged through the expression level of the TRBC1 antibody, and the cytotoxic function activity of the CTL cells is evaluated through the expression levels of Granzyme B and Perforin.

Novel antibodies and antibody fragments that specifically bind CD3 and compositions containing the antibodies or antibody fragments. Nucleic acids encoding the antibodies or antibody fragments thereof and host cells containing the same, and related uses, and therapeutic and diagnostic uses of these antibodies and antibody fragments.

The invention discloses a detection reagent, a kit and a method for detecting T lymphocyte immunophenotype before and after treatment of an MM patient through flow cytometry. Comprising a first antibody combination: an anti-CD3 antibody, an anti-CD45RA antibody, an anti-CD39 antibody, an anti-CD57 antibody, an anti-CCR7 antibody, an anti-CD28 antibody, an anti-CD95 antibody, an anti-TIGIT antibody, an anti-PD-1 antibody and an anti-CD8 antibody; the first group of antibodies comprises an anti-CD3 antibody, an anti-CD45RA antibody, an anti-CD39 antibody, an anti-CD127 antibody, an anti-CD25 antibody, an anti-CD36 antibody, an anti-CCR8 antibody, an anti-NRP1 antibody, an anti-PD-1 antibody and an anti-CD4 antibody, and the third group of antibodies comprises an anti-CD3 antibody, an anti-CD8 antibody, an anti-CD28 antibody, an anti-CD39 antibody, an anti-CD57 antibody, an anti-PD-1 antibody and an anti-TIGIT antibody; the kit is an anti-cTCF-1 antibody, an anti-cTOX antibody and an anti-cKi-67 antibody. The method has the advantages of few detection tubes, high antibody coverage rate, obvious cell grouping and strong systematicness.

The present invention relates to an induction medium and an expansion medium for inducing and amplifying TIL cells from tumor tissues, and a method for inducing and / or amplifying TIL cells. The induction medium comprises one or two selected from IL-7 and IL-15, IL-2, TNF-α, CD3 antibody and CD28 antibody. The expansion medium comprises one or two selected from IL-7 and IL-15, IL-2, TNF-α, CD3 antibody, CD28 antibody and CD137 antibody.

The present application provides antibodies comprising an antigen-binding fragment of an anti-CD3 antibody having tailor-made affinity to CD3 in low to medium range. In some embodiments, the antibody further comprises an antigen-binding fragment that specifically binds to a target antigen, such as HER2, CD20, TROP2, BCMA, or CD19. Also provided are anti-CD3 antibodies, masked anti-CD3 antibodies (including activatable anti-CD3 antibodies), anti-CD20 antibodies, and masked anti-HER2 antibodies (including activatable anti-HER2 antibodies). The antibodies described herein are useful for treatment of cancer.

The invention discloses a full-automatic multiplex fluorescent staining detection method for EBER, CD3 and CD20 and application of the full-automatic multiplex fluorescent staining detection method, and belongs to the technical field of biomarker detection. The invention relates to an EBER, CD3 and CD20 detection method, which comprises: carrying out digestion treatment on a sample to be detected, adding an EBER probe, and sequentially adding a primary antibody, a secondary antibody and a fluorescent dye A so as to complete color development; sequentially adding a CD3 antibody, an HRP polymer and a fluorescent dye B into the to-be-detected sample to finish CD3 dyeing; sequentially adding a CD20 antibody, an HRP polymer, a fluorescent dye C and a DAPI dye into a sample to be detected to finish CD20 dyeing; and observing or counting the dyeing result of the to-be-detected sample through fluorescence scanning equipment.

The invention belongs to the technical field of biological medicines, and particularly relates to an anti-B7H3 nano antibody and application thereof. The invention provides an anti-B7H3 nano antibody and application thereof, aiming at the problems that the existing B7H3 antibody is mainly a mouse monoclonal antibody and is large in molecular weight, poor in tissue penetrability, not easy to engineer and the like. According to the invention, a human B7H3 target spot is taken as an antigen, 15 anti-B7H3 specific nano antibodies are screened through a phage display technology, and the nano antibodies can be specifically combined with the B7H3 antigen, are high in specificity and affinity, and also have the advantages of small molecular weight, high stability, easiness in transformation, high solubility and the like. Meanwhile, the anti-B7H3 nano antibody and the anti-CD3 antibody OKT3scFv are connected in series to prepare the B7H3 / CD3 bispecific antibody, in-vivo and in-vitro experiments show that the B7H3 / CD3 bispecific antibody has a good anti-tumor effect, and the B7H3 / CD3 bispecific antibody can be applied to preparation of anti-tumor drugs and has a wide anti-tumor effect.

The present invention relates to humanized or chimeric CD3 antibodies. The present invention relates to humanized or chimeric antibodies that bind CD3. The invention further relates to bispecific antibodies, compositions, pharmaceutical compositions, uses of said antibodies in the treatment of disease and methods of treatment.

The invention discloses a bifunctional T cell adapter targeting CD14 and CD3 and an application of the bifunctional T cell adapter. Specifically, the invention provides a CD14 and CD3 targeting bifunctional T cell adapter, the CD14 and CD3 targeting bifunctional T cell adapter comprises a skeleton containing an IgG antibody constant region, the skeleton comprises two heavy chains and a light chain, one heavy chain comprises heavy chain constant regions CH1, CH2 and CH3, the other heavy chain comprises CH2 and CH3, the light chain comprises CL, the CD14 and CD3 targeting bifunctional T cell adapter is a heterotrimer, and the CD14 and CD3 targeting bifunctional T cell adapter is a heterotrimer. Specifically, the first subunit comprises a light chain variable region of an anti-CD14 antibody and a light chain in the skeleton, the second subunit comprises a heavy chain variable region of the anti-CD14 antibody and a heavy chain in the skeleton, and the third subunit comprises a heavy chain variable region of an anti-CD3 antibody and a light chain variable region. The bifunctional T cell adapter disclosed by the invention has an excellent tumor killing effect.

The invention discloses a spleen-targeted nano platform construction method suitable for tumor vaccination, and particularly relates to the field of vaccines.The spleen-targeted nano platform construction method comprises the steps that S1, CL15H6-DOPS LNPs, spherical polymer vesicles and erythrocyte membrane coated nano-particles are selected as spleen-targeted nano-carriers; s2, integrating an immunologic adjuvant; mn < 2 + > doped LNPs, ultrasonic response lipidosome and a CD3 antibody are selected to be coupled to serve as an integration material; s3, delivering in vivo; animal models are selected for in-vivo delivery and curative effect verification, and B16F10 melanoma mice, MC38 colon cancer mice and non-human primates are selected as the animal models respectively. By optimizing the chain length and the surface topological structure (such as spherical polymer vesicles) of the liposome, the spleen enrichment rate is remarkably increased, and the red marrow myeloid cell uptake efficiency is enhanced. By combining with common delivery of a manganese adjuvant, an STING channel is activated, secretion of type I interferon is promoted, and the proportion of antigen-specific CD8 + T cells and the tumor inhibition rate are increased.

The present application relates to an anti-CD3 antibody and its application. The present application develops a specific antibody molecule targeting CD3 epsilon chain, which can activate T cells by combining with CD3 epsilon on T cells. A T cell binding protein containing the CD3 antibody is further designed, which can specifically target and bind to CD3 epsilon on the surface of T cells in vivo and in vitro, so as to achieve moderate activation of T cells. The CAR lentivirus containing the T cell binding protein of the present application can induce the generation of CAR-T cells in vitro and in vivo, and the CAR-T cells have good tumor cell killing efficiency.

The application discloses an antibody targeting DLL3 and application thereof, and relates to the field of biological medicines. Specific anti-DLL3 nanobodies are screened in the embodiment of the application, and a bispecific antibody constructed from the anti-human DLL3 nanobody or humanized nanobody and an anti-human CD3 antibody is prepared, the obtained bispecific antibody has good antitumor activity, can be applied to preparation of at least one drug for preventing or treating a DLL3 expression abnormality related tumor or cancer disease including small cell lung cancer, and has wide application.

The present disclosure provides anti-CD3 monoclonal antibodies and related compositions, which can be used in any of a variety of therapeutic and diagnostic methods for the treatment of diseases and disorders, such as cancer and autoimmune diseases and disorders. The present disclosure also relates to bispecific antibodies comprising anti-CD3 antibodies. The present disclosure further relates to methods of treatment using such anti-CD3 monoclonal and bispecific antibodies. The present disclosure generally relates to anti-CD3 antibodies, compositions and methods using same.

The application belongs to the technical field of biological medicine, and discloses an in-situ vaccine type mRNA-tLNP preparation for solid tumor treatment and preparation and application thereof. The preparation is designed by double targets, so that CAR-T kills more tumor cells to overcome tumor heterogeneity, changes the tumor immune microenvironment through autocrine fusion proteins (anti-PD-1 scFv and TGFbetaRII, IL-15 and Flt3L, CD40L), promotes T cell proliferation, and recruits and activates dendritic cells, cross-presents new antigens in the tumor local part, and produces in-situ vaccination effects; circular RNA encoding the above proteins is prepared, and the circular RNA is wrapped by lipid nanoparticles modified by CD3 antibodies, so as to be directly delivered to the body, and a significant solid tumor treatment effect is produced.

Provided herein are novel human anti-CD3 antigen-binding polypeptides, treatments, nucleic acids, vectors, their preparation and their use in the treatment and / or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and / or treatment of various diseases.

The invention relates to a human peripheral blood cell immunotyping antibody combination and method based on flow cytometry. The antibody combination comprises an anti-CD3 antibody, an anti-CD4 antibody, an anti-CD8 antibody, an anti-EGFR antibody, an anti-CD25 antibody, an anti-CD127 antibody, an anti-CD45RA antibody, an anti-CCR7 antibody, an anti-CD27 antibody, an anti-PD-1 antibody, an antiTIGIT antibody and an anti-41BB antibody. The method comprises the following steps: mixing the antibody combination with a sample to be detected, incubating, performing flow cytometry detection to obtain detection data, and further judging the proportion and / or the number of target cell populations. According to the present invention, the optimal cell surface marker antibody combination is designed and obtained, the CAR-T cells in the sample are subjected to immune typing by using the 12-color antibody combination through the flow cytometry, the detection result is rapidly obtained, the CAR-T cell proportion of each phenotype is efficiently identified, and the method has high precision and high stability.

Provided herein are, inter alia, antibody compounds comprising an anti-immune cell antibody (e.g., anti-CD3 antibody) covalently bound to a CS-1-binding antibody; immune cells bound to compounds comprising an anti-immune cell antibody (e.g., anti-CD3 antibody) covalently bound to a CS-1-binding antibody; humanized OKT3 antibodies; pharmaceutical compositions; and methods for treating cancer, such as multiple myeloma.

Antibodies and antigen-binding fragments thereof having high affinity for CD3 and desirable developability profiles are provided, as are methods for making and using the same.

The present disclosure provides anti-commensal antibody (ACAb)-based profiles and methods of selecting a subject at risk of developing type 1 diabetes (T1D) for treatment with an anti-CD3 antibody. Also provided is a method of treating a subject at risk of developing T1D with an anti-CD3 antibody when the subject has an ACAb-based profile that predicts the subject is a responder the treatment. Further provided are ACAb-based profiles and methods of predicting that a subject at risk of developing T1D will progress to T1D.